Orphanet: Congenital hypothyroidism due to transplacental passage of TSH binding inhibitory antibodies

(*) Required fields.

You are (*)

If you have selected the “Other” category, please specify which type of user you are: *

Email address: *

Topic of your comment *

Epidemiology data

Clinical signs

Nomenclature and/or coding

Your message *

(3000 characters remaining)

Attention

Only comments seeking to improve the quality and accuracy of information on the Orphanet website are accepted. For all other comments, please send your remarks via contact us. Only comments written in English can be processed.

Orphanet doesn't provide personalised answers. To get in touch with the Orphanet team, please contact

Information provided in your contribution (including your email address) will be stocked in .CSV files that will be sent as an email to Orphanet's teams. These emails might be conserved in the teams' mailboxes, in our backoffice servers but will not be registered in our databases (for more information see our section General Data Protection Regulation and data privacy (GDPR) and Confidentiality).

Check this box if you wish to receive a copy of your message

Please reproduce the text below: *

Congenital hypothyroidism due to transplacental passage of TSH-binding inhibitory antibodies

Disease definition

Congenital hypothyroidism due to transplacental passage of maternal thyroid-stimulating hormone (TSH)-binding inhibitory antibodies is a type of transient congenital hypothyroidism (see this term), a thyroid hormone deficiency that is not permanent.

Summary

Epidemiology

Prevalence is estimated to be 1/100,000.

Clinical description

Patients may present with symptoms similar to those of permanent CH (see this term) or they may be asymptomatic.

Etiology

It is caused by the transfer of maternal TSH blocking antibodies, which can block the TSH receptor in the neonatal thyroid resulting in hypothyroidism in the infant. The effect can last up to 3-6 months after birth as maternal antibody levels fall.

Management and treatment

Treatment with l-thyroxine is usually required during this period.

Expert reviewer(s): Dr Stephen LAFRANCHI - Dr Maynika RASTOGI - Last update: August 2010

A summary on this disease is available in Deutsch (2010) Español (2010) Français (2010) Italiano (2010) Nederlands (2010) Português (2010)

Detailed information

Guidelines

Anesthesia guidelines
Czech (2017) - Orphananesthesia
English (2017) - Orphananesthesia
Español (2017) - Orphananesthesia

Disease review articles

Review article
English (2010) - Orphanet J Rare Dis

produced/endorsed by ERN(s) FSMR

produced/endorsed by FSMR(s)

The portal for rare diseases and orphan drugs

Search for a rare disease

Other search option(s)